[Erythrocyte filterability and treatment with pentoxifylline].
The purpose of our study was to verify the possibility of obtaining a reduction in the erythrocyte filtration rate and an improvement in the O2 tissue uptake in twenty patients suffering from insulin-dependent diabetes mellitus and diabetic angiopathy, randomly divided in two groups receiving pentoxifylline (1,200 mg/day for 30 days) or a placebo solution, respectively. The erythrocyte filtration rate decreased in patients treated with pentoxifylline and the difference of erythrocyte filtration rate between the two groups was statistically significant.
D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004912:Erythrocytes / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D010101:Oxygen Consumption; D010431:Pentoxifylline / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*; D014462:Ultrafiltration
D013805:Theobromine; D010431:Pentoxifylline
Filtrabilità eritrocitaria e trattamento con pentossifillina.